hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06275451, orgStudyIdInfo id: EssaiClinique_QUALI-RES, briefTitle: Qualitative Study of Emotional Regulation in Schizophrenia, acronym: QUALI-RES, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: University Hospital, Grenoble, class: OTHER, descriptionModule briefSummary: The main aim of this study is to investigate emotional regulation in individuals with schizophrenia using a qualitative methodology (semi-structured interview) and, therefore, from the person's point of view.Given the qualitative nature of the methodology used in this study, the investigators have no specific hypothesis. The investigators have a general hypothesis suggesting that the patients' discourse will enable us to highlight the emotional regulation difficulties described in the literature., conditionsModule conditions: Schizophrenia, conditions: Schizophrenia Schizoaffective, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Semi-structured interview, outcomesModule primaryOutcomes measure: Emotional regulation in schizophrenia, secondaryOutcomes measure: Factors influencing emotional regulation in schizophrenia, secondaryOutcomes measure: Improved emotional regulation in schizophrenia, secondaryOutcomes measure: Stages of emotional regulation in schizophrenia, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06275425, orgStudyIdInfo id: 4-2023-0429, briefTitle: Comparison of the Coughing Frequency of Remimazolam Total Intravenous Anesthesia Versus Inhalational Anesthesia, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-25, primaryCompletionDateStruct date: 2023-11-29, completionDateStruct date: 2023-11-29, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Yonsei University, class: OTHER, descriptionModule briefSummary: This study is a randomized controlled trial. Adult patients undergoing thyroidectomy under general anesthesia at Severance Hospital and Yonsei Cancer Center are included in tis study. For intervention group, patients receive anesthesia with total intravenous remimazolam, while for control group, patients receive anesthesia with inhalation anesthetic.The primary end point of the study is to determine whether coughing during endotracheal tube extubation is less when anesthesia is maintained with intravenous remimazolam compared to inhalation anesthetics. The secondary end points are cough score (graded into 4 levels), frequency of reoperation due to postoperative bleeding, These include the frequency of hypertension during the extubation process and whether additional painkillers are used in the recovery room., conditionsModule conditions: Thyroid Neoplasm, conditions: Cough, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: a single-blinded randomized controlled trial, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 106, type: ACTUAL, armsInterventionsModule interventions name: Total intravenous anesthesia with Byfavo, interventions name: Inhalation anesthesia with Sevoflurane, outcomesModule primaryOutcomes measure: Proportion of patients not coughing during postoperative extubation, secondaryOutcomes measure: Cough score, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, College of Medicine, Yonsei University,, city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06275386, orgStudyIdInfo id: 2.31/II/24, briefTitle: Drug-Coated Balloon in Native Chronic Total Occlusion Percutaneous Coronary Intervention, acronym: IMAGINATION, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: National Institute of Cardiology, Warsaw, Poland, class: OTHER, descriptionModule briefSummary: The IMAGINATION trial is an investigator-initiated, prospective, single-center study of symptomatic patients with a native chronic total occlusion (CTO) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) with a drug-coated balloon (DCB). Post-PCI IVUS and fractional flow reserve (FFR) at baseline and at 6-months follow-up will be performed. In addition, patients included in the coronary computed tomography angiography (CCTA) substudy will undergo photon-counting CCTA at 12-months follow-up. The aim of this study is to evaluate the efficacy and safety of DCB-only approach in native coronary CTO., conditionsModule conditions: Coronary Artery Disease, conditions: Total Occlusion of Coronary Artery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Paclitaxel Drug-coated balloon, outcomesModule primaryOutcomes measure: In-segment late lumen loss, secondaryOutcomes measure: Angiographic outcomes assessed directly post-PCI, secondaryOutcomes measure: HQ-IVUS outcomes assessed directly post-PCI, secondaryOutcomes measure: Physiologic outcomes assessed directly post-PCI, secondaryOutcomes measure: Angiographic outcomes at 6-months follow-up, secondaryOutcomes measure: HQ-IVUS outcomes at 6-months follow-up, secondaryOutcomes measure: Physiologic outcomes at 6-months follow-up, secondaryOutcomes measure: Computed tomographic outcomes at 12-months follow-up (CCTA substudy), secondaryOutcomes measure: Clinical outcomes at 12-months follow-up, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Institute of Cardiology, city: Warsaw, state: Mazowieckie, zip: 04-628, country: Poland, contacts name: Agnieszka Zdziennicka, role: CONTACT, email: azdziennicka@ikard.pl, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06275373, orgStudyIdInfo id: 20-10974, briefTitle: The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction, acronym: Teprotumumab, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-05-12, primaryCompletionDateStruct date: 2026-05-12, completionDateStruct date: 2027-12-12, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Walter Reed National Military Medical Center, class: FED, descriptionModule briefSummary: This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang)., conditionsModule conditions: Thyroid Eye Disease, conditions: Graves Ophthalmopathy, conditions: Graves Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Teprotumumab Injection [Tepezza], outcomesModule primaryOutcomes measure: Ophthalmological Clinical Activity Score (CAS) scoring, primaryOutcomes measure: Thyroid stimulating immunoglobulin, secondaryOutcomes measure: HLA subtypes, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Walter Reed National Military Medical Center, status: RECRUITING, city: Bethesda, state: Maryland, zip: 20889, country: United States, contacts name: Thanh D Hoang, DO, role: CONTACT, phone: 301-295-5165, phoneExt: 6220, email: thanh.d.hoang.mil@health.mil, contacts name: Iris E Morris, PhD, role: CONTACT, phone: 3013194599, email: iris.e.morris3.civ@health.mil, geoPoint lat: 38.98067, lon: -77.10026, hasResults: False
protocolSection identificationModule nctId: NCT06275334, orgStudyIdInfo id: 9133, briefTitle: Dinutuximab Beta at the HUS and the Toulouse Oncopole, acronym: DNB, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-28, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-11-28, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: University Hospital, Strasbourg, France, class: OTHER, descriptionModule briefSummary: In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse., conditionsModule conditions: Neuroblastoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, outcomesModule primaryOutcomes measure: Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse., eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Service de Pharmacie - Stérilisation - CHU de Strasbourg - France, status: RECRUITING, city: Strasbourg, zip: 67091, country: France, contacts name: Anne EL AATMANI, Pharm, PhD, role: CONTACT, phone: 33 3 88 12 78 06, email: Anne.ELAATMANI@chru-strasbourg.fr, contacts name: Emilie BERTHON, Pharm, PhD, role: CONTACT, phone: 33 3 88 12 78 06, email: emilieberthon@orange.fr, contacts name: Anne EL AATMANI, Pharm, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Emilie BERTHON, PhamD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Sophie PERRIAT, PhamD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 48.58392, lon: 7.74553, hasResults: False
protocolSection identificationModule nctId: NCT06275321, orgStudyIdInfo id: Elena Garcia Roca, briefTitle: Physical Exercise Benefits for Cancer Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-11-05, primaryCompletionDateStruct date: 2024-07-27, completionDateStruct date: 2025-07-30, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Universitat Jaume I, class: OTHER, descriptionModule briefSummary: The purpose of the study was to analyze the effect of a synchronous-supervised online home-based group during a 6-month exercise program on physical fitness, body composition and adherence compared to an exercise recommendation group of patients undergoing breast cancer treatment without supervision., conditionsModule conditions: Cancer, Breast, conditions: Sports Physical Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: A prospective ramonized clinical trial with two groups, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Synchronous-supervised online home-based group, interventions name: Exercise recommendation group, outcomesModule primaryOutcomes measure: Cardiorrespiratory fitness, primaryOutcomes measure: Strength - Chair Stand (repetitions), primaryOutcomes measure: Flexibility, primaryOutcomes measure: Incidence of treatments on quality of live assessed by EORTIC QLQ-C30, primaryOutcomes measure: Adherence, primaryOutcomes measure: Rating of perceived exertion, primaryOutcomes measure: Strength - Hand Grip (Kilograms), primaryOutcomes measure: Strength - Squat Jump (height in centimeters), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jaume I University, status: RECRUITING, city: Castellón De La Plana, state: Castellón, zip: 12071, country: Spain, contacts name: Elena Garcia Roca, MSc, role: CONTACT, phone: +34 629112367, email: garciroc@uji.es, contacts name: Eladio J Collado-Boira, PhD, role: CONTACT, phone: +34 606133368, email: colladoe@uji.es, geoPoint lat: 39.98567, lon: -0.04935, hasResults: False
protocolSection identificationModule nctId: NCT06275308, orgStudyIdInfo id: STUDY21100163, briefTitle: Effect of Raised End-Tidal pCo2 on Choroidal Volume, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-27, primaryCompletionDateStruct date: 2025-02-27, completionDateStruct date: 2025-02-27, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: University of Pittsburgh, class: OTHER, descriptionModule briefSummary: This study is to investigate the relationship between arterial carbon dioxide (CO2) concentration and vitreous pressure on the choroidal volume by integrated intraoperative OCT imaging under eye exams under anesthesia., conditionsModule conditions: Intraocular Pressure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a descriptive case series., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Ventilation manipulation, outcomesModule primaryOutcomes measure: Intraocular Pressure (IOP) (mmHg), secondaryOutcomes measure: Choroidal thickness ( microns), eligibilityModule sex: ALL, maximumAge: 8 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of Pittsburgh Medical Center, status: RECRUITING, city: Pittsburgh, state: Pennsylvania, zip: 15224, country: United States, contacts name: Amy Monroe, MPH, MBA, role: CONTACT, email: monroeal@upmc.edu, contacts name: Kanwal Nischal, MD,FRCOphth, role: PRINCIPAL_INVESTIGATOR, contacts name: Lieu Tran, MD, role: SUB_INVESTIGATOR, geoPoint lat: 40.44062, lon: -79.99589, hasResults: False
protocolSection identificationModule nctId: NCT06275295, orgStudyIdInfo id: ZRJY2021-BJ08-03-01-01, briefTitle: A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-12-24, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: China-Japan Friendship Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC） in progressive pulmonary fibrosis., conditionsModule conditions: Pulmonary Fibrosis, conditions: Transbronchial Cryobiopsy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, outcomesModule primaryOutcomes measure: The diagnostic rate of MDD2 based on TBLC, secondaryOutcomes measure: The diagnostic rate of MDD1, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06275269, orgStudyIdInfo id: ZRJY2021-BJ08-04-02, briefTitle: Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: China-Japan Friendship Hospital, class: OTHER, descriptionModule briefSummary: This study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. The comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. The safety and effectiveness will be compared to determine the relative merits of the two treatment methods., conditionsModule conditions: Subglottic Stenosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-Guided, interventions name: Translaryngeal Endoscopic Mucosal Injection, outcomesModule primaryOutcomes measure: Incidence of Short-Term Postoperative Complications, secondaryOutcomes measure: Overall medical expenses incurred by patients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06275256, orgStudyIdInfo id: HS26226, briefTitle: Outcomes of MIST for BPH: A Single-Institution Prospective Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: University of Manitoba, class: OTHER, descriptionModule briefSummary: The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile., conditionsModule conditions: Benign Prostatic Hyperplasia, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Rezum, interventions name: iTind, outcomesModule primaryOutcomes measure: Symptom Scores, primaryOutcomes measure: Uroflow, primaryOutcomes measure: Uroflow, primaryOutcomes measure: Symptom Scores, primaryOutcomes measure: Symptom Scores, primaryOutcomes measure: Symptom Scores, secondaryOutcomes measure: Pain Scale, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Men's Health Clinic, city: Winnipeg, state: Manitoba, zip: R3K 1M3, country: Canada, contacts name: Premal Patel, MD, role: CONTACT, phone: 204-221-4476, email: ppatel5@hsc.mb.ca, contacts name: Harliv Dhillon, BSc, role: CONTACT, phone: 2049904153, email: harlivmhc@gmail.com, geoPoint lat: 49.8844, lon: -97.14704, hasResults: False
protocolSection identificationModule nctId: NCT06275243, orgStudyIdInfo id: ETICA-ULE-021-2022, briefTitle: Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-07-06, primaryCompletionDateStruct date: 2023-03-13, completionDateStruct date: 2024-03-22, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Universidad de León, class: OTHER, collaborators name: Consejo General de Colegios Oficiales de Enfermería España, descriptionModule briefSummary: The general objective of this randomized and longitudinal clinical study was to estimate the frequencies of ApoE variants both in the user population of the "Messengers of Peace" Residences and the "Associations of Relatives of Alzheimer's Patients" in Castile y Leon, since, due to its geographical location at the crossroads, it has received multiple genetic contributions from both northern Europe, the Mediterranean area and northern Africa.The main questions it aims to answer are:* What are the allelic frequencies of ApoE variants in the population of individuals with Alzheimer's disease in Castile and Leon?* Is there a correlation between the ApoE4 variant and the lipid profile in the blood of individuals with Alzheimer's disease in this region?, conditionsModule conditions: Alzheimer Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: It is a longitudinal randomised clinical study, in which two study groups were used. A group of cases diagnosed with Alzheimer's disease and a control group of healthy individuals without Alzheimer's disease., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 511, type: ACTUAL, armsInterventionsModule interventions name: Kit Buccal swab collection & stabilization de Canvax®, interventions name: Cholesterol levels according to ApoE Genotype, interventions name: Assessing cardiovascular risk factors in all participants, outcomesModule primaryOutcomes measure: Distribution of ApoE variants in the Alzheimer's disease population diagnosed in Castile and Leon., secondaryOutcomes measure: Cardiovascular factors in individuals with Alzheimer's disease and healthy subjects., secondaryOutcomes measure: ApoE genotypes and cholesterol levels in the Alzheimer's disease population diagnosed in Castile and Leon., eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of León, city: León, zip: 240071, country: Spain, geoPoint lat: 42.60003, lon: -5.57032, hasResults: False